Brenntag SE lifts 2026 earnings guidance. UBS sticks with neutral rating

By Thomas Clarke, Operations & Strategy desk. Reviewed on June 30, 2026 at 3:11 p.m. ET.

Brenntag SE (ISIN DE000A1DAHH0) has raised its earnings guidance for 2026 after reporting strong preliminary operating EBITDA for the second quarter, a move that kept UBS at a neutral rating with a €60 price target on the chemical distributor. According to market data, Brenntag stock trades in the mid-€50 range on Xetra, while its ADR changes hands at a little above $12 on the OTC market.

Preliminary Q2 EBITDA and guidance hike

According to corporate disclosures summarized by Onvista's Brenntag overview, the company released an EQS ad hoc announcement on June 22, 2026 outlining preliminary operating EBITDA for the second quarter of 2026 and a higher full-year forecast. The notice reported a preliminary operating EBITDA of around €450 million for the quarter, indicating that Brenntag's business proved resilient despite a mixed macro environment and ongoing geopolitical disruptions that affect chemical supply chains.

In the same ad hoc communication described by the Onvista feed, Brenntag lifted its guidance for operating EBITDA in the 2026 financial year from a previous corridor of €1.15 billion to €1.35 billion to a new range of €1.25 billion to €1.40 billion. The revised guidance reflects management's assessment of continued demand in key end markets and improved margin dynamics in its distribution operations. At the same time, the company flagged risks from potentially weaker volume trends in the second half of the year, underlining that the outlook remains cautious even after the upgrade.

UBS reiterates neutral stance after the update

The revised guidance prompted a fresh assessment by UBS, which maintained its neutral rating on Brenntag while confirming a €60 price target. This stance is summarized in an analyst commentary available via the UBS analysis reported by FinanzNachrichten. UBS cited the preliminary quarterly operating EBITDA figure and the new guidance band as key inputs, suggesting that the updated numbers are broadly in line with the analyst's expectations and justify a neutral view rather than a more positive or negative rating.

The UBS commentary noted that the second-quarter operating EBITDA came in ahead of the market consensus, supporting the credibility of the guidance raise. However, the bank also highlighted that the demand backdrop in parts of the chemical distribution landscape remains fragile, which could constrain upside over the medium term. For investors who follow US-listed chemical distributors such as Univar Solutions or global peers covered on US exchanges, the neutral stance by UBS provides one comparative perspective on how Brenntag's numbers stack up against broader sector dynamics, even though Brenntag itself is primarily traded in Europe with an ADR on the OTC market tracked by US platforms like MarketBeat's BNTGY page.

Chemical distribution network and key services

Brenntag SE operates as a global chemical and ingredients distributor, connecting large producers with industrial and specialty customers through a network of warehouses, blending facilities and regional logistics hubs. The company structures its activities around business units such as Essentials, which focuses on large-volume industrial chemicals, and Specialties, which handles high-value formulations and technical support for sectors including food, pharmaceuticals and coatings. This dual approach allows Brenntag to tailor its service offering to customers with different needs, ranging from standard commodity chemicals to complex application-specific solutions.

In the food and beverage area, Brenntag companies provide ingredient sourcing and formulation support across Asia and other regions. Listings in directories like Asia Food Beverages' supplier overview show entities such as Brenntag Pte Ltd among distributors serving manufacturers and brands. These operations typically involve supplying functional ingredients, flavors, preservatives and texturizers, along with regulatory guidance and quality assurance processes. The combination of product portfolio breadth and application expertise is a core part of Brenntag's business model, positioning the group as a partner for companies that prefer outsourcing parts of their procurement and formulation work.

Stock and ADR trading levels

As of late June 2026, Brenntag's shares trade on Xetra in Frankfurt, with prices around the mid-€50 level. Market data snapshots compiled by platforms such as MarketScreener for Brenntag SE and German portals like Onvista show recent Xetra prices in a range just above €53, with trading volumes in the tens of thousands of shares per day and volatility in the low-20-percent annualized band. The stock sits below a 52-week high in the low-€60 range, indicating that while the guidance hike has supported sentiment, the market has not repriced the company to its recent peak.

In the United States, Brenntag is present through the BNTGY ADR on the OTC market. According to data summarized on MarketBeat's Brenntag ADR page, the ADR recently changed hands at $12.16 as of June 29, 2026, with the price up about 5 percent from the start of the year. For US retail investors, the ADR provides access to Brenntag's equity story without directly trading on the Frankfurt exchange, although liquidity and trading conditions differ from major US-listed chemical distributors. MarketBeat also points to consensus views around the name, including a rating spread that currently includes a consensus recommendation in the reduce category, reflecting a cautious stance among covering analysts despite the latest guidance adjustment.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.